The Wnt signaling pathway as a potential target for therapies to enhance bone repair

Science Translational Medicine

Volumn 2, Issue 42, 2010, Pages

  Einhorn, Thomas A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1; WNT PROTEIN;

BONE DENSITY; BONE MATRIX; BONE REGENERATION; BONE REMODELING; CELL STIMULATION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; FRACTURE HEALING; FRACTURE NONUNION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LOSS OF FUNCTION MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGENERATIVE MEDICINE; REVIEW; SIGNAL TRANSDUCTION; SPINE FUSION; TIBIA FRACTURE; ANIMAL; ARTICLE; BONE; GENETICS; INJURY; METABOLISM; PHYSIOLOGY;

ANIMALS; BONE AND BONES; FRACTURE HEALING; HUMANS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 77955590181     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001149     Document Type: Review

References (21)

1. M. R. Urist, Bone: Formation by autoinduction. Science 150, 893-899 (1965).
2. M. R. Urist, B. F. Silverman, K. Büring, F. L. Dubuc, J. M. Rosenberg, The bone induction principle. Clin. Orthop. Relat. Res. 53, 243-283 (1967).
3. A. J. Celeste, J. A. Iannazzi, R. C. Taylor, R. M. Hewick, V. Rosen, E. A. Wang, J. M. Wozney, Identification of transforming growth factor β family members present in bone-inductive protein purified from bovine bone. Proc. Natl. Acad. Sci. U.S.A. 87, 9843-9847 (1990).
4. A. Praemer, S. Furner, D. P. Rice, Musculoskeletal Conditions in the United States (American Academy of Orthopaedic Surgeons, Park Ridge, IL, 1999), pp. 185-124.
5. D. G. Schultz, P000058 letter of approval, 2 July 2002 [Center for Devices and Radiological Health, U.S. Department of Health and Human services (HHS)]. Available at http://www.accessdata.fda.gov/cdrh-docs/pdf/ p000058a.pdf (accessed 4 August 2009).
6. D. G. Schultz, P000054 letter of approval, 30 April 2004 (Center for Devices and Radiological Health, HHS). Available at http://www.accessdata.fda. gov/cdrh-docs/pdf/ p000054a.pdf (accessed 4 August 2009).
7. D. G. Schultz, HDE H0100002 letter of approval, 17 November 2001 (Center for Devices and Radiological Health, HHS).
8. D. G. Schultz, HDE H0200008 letter of approval, 7 May 2004 (Center for Devices and radiological Health, HHS).
9. T. W. Axelrad, T. A. Einhorn, Bone morphogenetic proteins in orthopaedic surgery. Cytokine Growth Factor Rev. 20, 481-488 (2009).
10. E. Canalis, A. Giustina, J. P. Bilezikian, Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905-916 (2007).
11. S. Minear, P. Leucht, J. Jiang, B. Liu, A. Zeng, C. Fuerer, R. Nusse, J. A. Helms, Wnt proteins promote bone regeneration. Sci. Transl. Med. 2, 29ra30 (2010).
12. M. L. Johnson, G. Gong, W. Kimberling, S. M. Reckér, D. B. Kimmel, R. B. Recker, Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13). Am. J. Hum. Genet. 60, 1326-1332 (1997).
13. R. D. Little, J. P. Carulli, R. G. Del Mastro, J. Dupuis, M. Osborne, C. Folz, S. P. Manning, P. M. Swain, S. C. Zhao, B. Eustace, M. M. Lappe, L. Spitzer, S. Zweier, K. Braunschweiger, Y. Benchekroun, X. Hu, R. Adair, L. Chee, M. G. FitzGerald, C. Tulig, A. caruso, N. Tzellas, A. Bawa, B. Franklin, S. McGuire, X. Nogues, G. Gong, K. M. Allen, A. Anisowicz, A. J. Morales, P. T. Lomedico, S. M. Recker, P. Van Eerdewegh, R. R. Recker, M. L. Johnson, A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70, 11-19 (2002).
14. L. M. Boyden, J. Mao, J. Belsky, L. Mitzner, A. Farhi, M. A. Mitnick, D. Wu, K. Insogna, R. P. Lifton, High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513-1521 (2002).
15. Y. Gong, R. B. Slee, N. Fukai, G. Rawadi, S. Roman-Roman, A. M. Reginato, H. Wang, T. Cundy, F. H. Glorieux, D. Lev, M. Zacharin, K. Oexle, J. Marcelino, W. Suwairi, S. Heeger, G. Sabatakos, S. Apte, W. N. Adkins, J. Allgrove, M. Arslan- Kirchner, J. A. Batch, P. Beighton, G. C. Black, R. G. Boles, L. M. Boon, C. Borrone, H. G. Brunner, G. F. Carle, B. Dallapiccola, A. De Paepe, B. Floege, M. L. Halfhide, B. Hall, R. C. Hennekam, T. Hirose, A. Jans, H. Jüppner, C. A. Kim, K. Keppler-Noreuil, A. Kohlschuetter, D. Lacombe, M. Lambert, E. Lemyre, T. Letteboer, L. Peltonen, R. S. Ramesar, M. Romanengo, H. Somer, E. Steichen-Gersdorf, B. Steinmann, B. Sullivan, A. Superti-Furga, W. Swoboda, M. J. van den Boogaard, W. Van Hul, M. Vikkula, M. Votruba, B. Zabel, T. Garcia, R. Baron, B. R. Olsen, M. L. Warman, Osteoporosis- Pseudoglioma Syndrome Collaborative Group, LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513-523 (2001).
16. S. M. Ott, Sclerostin and Wnt signaling - The pathway to bone strength. J. Clin. Endocrinol. Metab. 90, 6741-6743 (2005).
17. L. Van Wesenbeeck, E. Cleiren, J. Gram, R. K. Beals, O. Bénichou, D. Scopelliti, L. Key, T. Renton, C. Bartels, Y. Gong, M. L. Warman, M. C. De vernejoul, J. Bollerslev, W. Van Hul, Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am. J. Hum. Genet. 72, 763-771 (2003).
18. W. Balemans, N. Patel, M. Ebeling, E. Van Hul, W. Wuyts, C. Lacza, M. Dioszegi, F. G. Dikkers, P. Hildering, P. J. Willems, J. B. Verheij, K. Lindpaintner, B. Vickery, D. Foernzler, W. Van Hul, Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91-97 (2002).
19. W. Balemans, E. Cleiren, U. Siebers, J. Horst, W. Van Hul, A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone 36, 943-947 (2005).
20. X. Li, Y. Zhang, H. Kang, W. Liu, P. Liu, J. Zhang, S. E. Harris, D. Wu, Sclerostin binds to LrP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883-19887 (2005).
21. Competing interests: T.A.E. receives consulting fees from Smith and Nephew, Anika, Lilly, Kuros, and Amgen. He holds ownership interest (stocks, stock options, or other ownership interest, excluding diversified mutual funds) in Biomineral Holdings, Healthpointcapital, OsteoGenix, and Implant Protection. He is a member of the Smith and Nephew scientific review board and of the Osteotech scientific advisory board and receives royalties from Osteotech.